What dose and formulation of GnRH agonist do you use for ovarian suppression in young breast cancer patients?
Do you use a q4 week or q12 week formulation? If you use both in your practice, what factors into your decision making for either one?
Community PollStarted
How do you achieve ovarian suppression in young breast cancer patients?
83 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Medical Oncology · Indiana University School of Medicine
Answered on
Available data is largely with the monthly formulation. I don't have a strong preference for which LHRH agent (though some payers might). The q12-week depot formulation may not maintain full suppression for younger patients. Here is my pragmatic strategy
- Start with monthly (q4 week). If not tolerat...
Join for free or sign in to see the full answer